PMID- 23645730
OWN - NLM
STAT- MEDLINE
DCOM- 20130626
LR  - 20151119
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 33
IP  - 5
DP  - 2013 May
TI  - Identification of HLA class I-binding peptides derived from unique 
      cancer-associated proteins by mass spectrometric analysis.
PG  - 1853-9
AB  - BACKGROUND/AIM: Since antigenic peptides of the cancer-associated antigens 
      presented on human leukocyte antigen (HLA) molecules are recognized by specific 
      cytotoxic T-lymphocytes, they have the potential to becoming effective peptide 
      vaccines for cancer immunotherapy. MATERIALS AND METHODS: Peptides binding to 
      HLA-A*0201 and HLA-A*2402 obtained from human prostate cancer cells by 
      acid-elution were analyzed by liquid chromatography-tandem mass spectrometry 
      (LC-MS/MS) and source proteins of the peptides were determined based on the 
      HLA-binding capacity listed on the Syfpeithi. RESULTS: We identified TKLSA 
      possibly derived from absent in melanoma 1-like protein (AIM1L), and RLRYT from 
      trans-membrane protein-191C (TMEM 191C) or c20orf201. Messenger RNAs encoding 
      these proteins were expressed in various cancer cell types but none or very few 
      in non-cancerous tissues except for testis, cerebellum and ovary. CONCLUSION: HLA 
      class I-binding peptides of unique cancer-associated proteins were identified by 
      MS analysis, and might become a promising tool for the generation of novel cancer 
      vaccines.
FAU - Kamata, Yuko
AU  - Kamata Y
AD  - Department of Oncology, Institute of DNA Medicine, The Jikei University School of 
      Medicine, 3-25-8 Nishi-shimbashi Minato-ku, Tokyo 105-8461 Japan. 
      ykama@jikei.ac.jp
FAU - Kuhara, Akiko
AU  - Kuhara A
FAU - Iwamoto, Takeo
AU  - Iwamoto T
FAU - Hayashi, Kazumi
AU  - Hayashi K
FAU - Koido, Shigeo
AU  - Koido S
FAU - Kimura, Takahiro
AU  - Kimura T
FAU - Egawa, Shin
AU  - Egawa S
FAU - Homma, Sadamu
AU  - Homma S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Peptide Fragments)
SB  - IM
MH  - Biomarkers, Tumor/*metabolism
MH  - Chromatography, Liquid
MH  - Histocompatibility Antigens Class I/immunology/*metabolism
MH  - Humans
MH  - Neoplasms/immunology/*metabolism
MH  - Peptide Fragments/immunology/*metabolism
MH  - *Spectrometry, Mass, Electrospray Ionization
MH  - *Tandem Mass Spectrometry
MH  - Tumor Cells, Cultured
OTO - NOTNLM
OT  - HLA class-I
OT  - antigenic peptide
OT  - cancer associated antigen
OT  - mass spectrometric analysis
OT  - prostate cancer
EDAT- 2013/05/07 06:00
MHDA- 2013/06/28 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/05/07 06:00 [entrez]
PHST- 2013/05/07 06:00 [pubmed]
PHST- 2013/06/28 06:00 [medline]
AID - 33/5/1853 [pii]
PST - ppublish
SO  - Anticancer Res. 2013 May;33(5):1853-9.